Table 3.

Standardized incidence ratios for AIDS-defining and non-AIDS-defining cancers.

Cancer type	Observed	SIR (95% CI)
AIDS-defining cancer
Kapos sarcoma	68	5600 (4400–7200)
Non-Hodgkin’s lymphoma	55	23.1 (17.8–30.0)
Diffuse large B cell	26	30.8 (20.1–45.3)
Primary CNS	21	2100 (1300–3200)
Burkitt	2	26.3 (3.2–94.8)
Other/unknown	6	4.8 (1.7–10.4)
Cervical	15	16.6 (9.3–27.4)
Non-AIDS-defining cancer
Head and neck	14	5.1 (2.8–8.6)
Esophagus	3	5.2 (1.1–15.1)
Stomach	2	2.4 (0.3–8.8)
Small intestine	0	0 (0–11.1)
Colon and rectum	2	0.5 (0.1–1.9)
Anal	10	39.0 (18.7–71.7)
Liver	13	16.5 (8.8–28.2)
Pancreas	1	1.0 (0.03–5.7)
Lung	29	5.5 (3.7–8.0)
Bones and joints	0	0 (0–29.3)
Soft tissue	0	0 (0–7.8)
Melanoma	4	4.0 (1.1–10.1)
Breast	3	0.6 (0.1–1.8)
Uterus	0	0 (0–6.6)
Ovary	0	0 (0–10.3)
Vagina and vulva	0	0 (0–30.3)
Prostate	5	0.6 (0.2–1.5)
Testis	0	0 (0–5.5)
Penis	1	24.2 (0.6–134.7)
Bladder	4	4.1 (1.1–10.5)
Kidney	5	2.9 (1.0–6.8)
Brain	0	0 (0–5.2)
Thyroid	0	0 (0–3.7)
Hodgkin’s lymphoma	8	9.8 (4.2–19.2)
Multiple myeloma	2	3.0 (0.4–10.7)
Leukemia	0	0 (0–3.6)
Mesothelioma	0	0 (0–0.1)
Miscellaneous/other	3	4.0 (0.8–8.3)

SIR, standardized incidence ratio; CI, confidence interval.